[
    [
        {
            "time": "",
            "original_text": "【广证恒生医药】健帆生物（300529）-业绩点评-灌流器肾病和肝病领域齐发力，2018年前三季度业绩50%超预期高速增长",
            "features": {
                "keywords": [
                    "健帆生物",
                    "灌流器",
                    "肾病",
                    "肝病",
                    "业绩点评",
                    "前三季度",
                    "50%增长"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【广证恒生医药】健帆生物（300529）-业绩点评-灌流器肾病和肝病领域齐发力，2018年前三季度业绩50%超预期高速增长",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        }
    ]
]